(A) Decrease in Soret band absorbance; (B) images and the percentages of metmyoglobin (MetMb), deoxymyoglobin (DeoMb) and oxymyoglobin (OxyMb) in native Mb and Mb-GlcN conjugates over glycation period from 0.5 to 12 days. by Yuliya Hrynets (800300)

“…<p>(A) Decrease in Soret band absorbance; (B) images and the percentages of metmyoglobin (MetMb), deoxymyoglobin (DeoMb) and oxymyoglobin (OxyMb) in native Mb and Mb-GlcN conjugates over glycation period from 0.5 to 12 days.…”

Mean liver weight (g) (A), liver weight/body ratio (B), hepatic triglyceride (mg/g) (C) and hepatic steatosis quantification (% area) (D) upon completion of the treatment phase. by Elsie D. Oduor (22521785)

This is the raw data of IHC-2 、qPCR、Masson and HE in Rat、qPCR in human peritoneal solution and qPCR in Met-5A cell. by Yangyang Yin (14323701)

Subjects:

Cardamonin decreased the protein expression of lipogenic proteins. by Peiguang Niu (17044532)

Decrease of muscle weakness and degeneration with mutants of UPS components. by Cécile Ribot (11944875)

Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR. by Jordan A. Gunning (18143970)

Pre-treatment of IOZCAS-Spex-II cells with CPT and HCPT decreased Topo1 specific activity in a time-dependent manner. by Lan Zhang (90951)

Pre-treatment of IOZCAS-Spex-II cells with CPT and HCPT decreased Topo1 specific activity in a dose-dependent manner. by Lan Zhang (90951)

HRMECs treated with 3-Deazaneplanocin A (DZNep) chemical inhibitor demonstrated increased miR-200b and decreased VEGF expression. by Michael Anthony Ruiz (726055)

“…[NG = 5mM D-glucose, HG = 25mM D-glucose, NG+DMSO = 5mM D-glucose + 0.05% DMSO, HG+DMSO = 25mM D-glucose + 0.05% DMSO, NG+DZNEP = 5mM D-glucose + 5μM DZNep, HG+DZNEP = 25mM + 5μM DZNep; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to β-actin for VEGF and U6 for miR-200b, expressed as a fold change of NG].…”

Fig 5 - by Maria Alice Miranda Bezerra Medeiros (11752002)

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Doxorubicin concentrations in skeletal muscle groups following the IP administration of (A) 1.5 mg kg-1 or (B) 4.5 mg kg-1 of Doxorubicin. by Sergio Fabris (799604)

Aggrecan knockdown ATDC5 chondroprogenitor cells have decreased Alcian blue staining and absorbance levels compared to control cells after ITS stimulation. by Juanita K. Hodax (6848540)

Medication tolerability, discontinuations, adherence over the 8-week study period. by Judith I. Tsui (5983160)

Subjects:

Medication satisfaction over 8-week study medication period. by Judith I. Tsui (5983160)

Subjects:

Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

Subjects:

Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

Subjects:

Basal and radiation-induced ROS in DC lymphocytes. by Larisa Pereboeva (322533)

Ethanol withdrawal (EW) decreases GluN2A subunit levels. by Marina Rubio (345805)

“…<p>NMDA subunit protein levels measured by Western blot analysis: GluN2A levels (B) decrease during ethanol withdrawal, whereas the levels of GluN1 (A) and GluN2B (C) remain unaltered. …”

Blockade of CB₁ receptors does not prevent the anandamide-induced decrease in locomotor activity and rearing. by Adriaan W. Bruijnzeel (2605954)

“…<p>Rats were treated with rimonabant (5 mg/kg, ip) and anandamide (10 mg/kg, ip) and horizontal (A) and vertical beam breaks (B) were assessed in the small open field. …”